

Special Issue

Research in Vaccine Adjuvants: Innovations and Challenges

Message from the Guest Editors

This Special Issue, "Research in Vaccine Adjuvants: Innovations and Challenges", aims to address these challenges and highlight the latest innovations in adjuvant research. We invite submissions on a variety of topics, including the following:

- New adjuvant materials and systems: exploring novel adjuvants derived from natural sources, synthetic polymers, or biotechnological approaches.
- Mucosal vaccine adjuvants: investigation of adjuvants that enhance the immunogenicity of mucosal vaccines, which are essential for the prevention of infection at mucosal surfaces.
- Mechanisms of adjuvant action: the study of the underlying mechanisms by which adjuvants interact with the immune system to enhance vaccine responses.
- Adjuvant safety and tolerability: evaluating the safety and tolerability of new adjuvants in preclinical and clinical studies.

We welcome original research articles, reviews, and perspectives that contribute to advancing our understanding of vaccine adjuvants. By addressing these topics, we aim to foster new insights and drive innovations in vaccine adjuvant research.

Guest Editors

Prof. Dr. Haibo Li

National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China

Prof. Dr. Hongwu Sun

National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing 400038, China

Deadline for manuscript submissions

31 October 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/222924

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).